Changing Use of Antibiotics in Community-based Outpatient Practice, 1991-1999
Overview
Affiliations
Background: Judicious use of antibiotics can slow the spread of antimicrobial resistance. However, overall patterns of antibiotic use among ambulatory patients are not well understood.
Objective: To study patterns of outpatient antibiotic use in the United States, focusing on broad-spectrum antibiotics.
Design: Cross-sectional survey in three 2-year periods (1991-1992, 1994-1995, and 1998-1999).
Setting: The National Ambulatory Medical Care Survey, a nationally representative sample of community-based outpatient visits.
Patients: Patients visiting community-based outpatient clinics.
Measurements: Rates of overall antibiotic use and use of broad-spectrum antibiotics (azithromycin and clarithromycin, quinolones, amoxicillin-clavulanate, and second- and third-generation cephalosporins). All comparisons were made between the first study period (1991-1992) and the final study period (1998-1999).
Results: Between 1991-1992 and 1998-1999, antibiotics were used less frequently to treat acute respiratory tract infections, such as the common cold and pharyngitis. However, use of broad-spectrum agents increased from 24% to 48% of antibiotic prescriptions in adults (P < 0.001) and from 23% to 40% in children (P < 0.001). Use of broad-spectrum antibiotics increased across many conditions, increasing two- to threefold as a percentage of total antibiotic use for a variety of diagnoses in both adults and children. By 1998-1999, 22% of adult and 14% of pediatric prescriptions for broad-spectrum antibiotics were for the common cold, unspecified upper respiratory tract infections, and acute bronchitis, conditions that are primarily viral.
Conclusions: Antibiotic use in ambulatory patients is decreasing in the United States. However, physicians are increasingly turning to expensive, broad-spectrum agents, even when there is little clinical rationale for their use.
Abebe R, Ayal B, Alemu M, Zeleke T Drugs Context. 2024; 13.
PMID: 38742144 PMC: 11090269. DOI: 10.7573/dic.2023-12-2.
Harrigan J, Hamilton K, Cressman L, Bilker W, Degnan K, David M Clin Infect Dis. 2024; 78(5):1120-1127.
PMID: 38271275 PMC: 11093661. DOI: 10.1093/cid/ciad754.
Tesfaw Addis G, Dagnew S, Anagaw A, Ayele T, Tadesse T Heliyon. 2023; 9(7):e18049.
PMID: 37449097 PMC: 10336787. DOI: 10.1016/j.heliyon.2023.e18049.
Dereje B, Yibabie S, Keno Z, Megersa A J Pharm Policy Pract. 2023; 16(1):62.
PMID: 37165415 PMC: 10173574. DOI: 10.1186/s40545-023-00568-7.
Hemmami H, Seghir B, Zeghoud S, Ben Amor I, Kouadri I, Rebiai A Molecules. 2023; 28(4).
PMID: 36838819 PMC: 9959599. DOI: 10.3390/molecules28041834.